BJDX logo

BLUEJAY DIAGNOSTICS INC

BJDXNASDAQ
🏆 #5210 by market capUS Equity
$0.95▼ $0.01 (−0.84%)
Live
🔔
Track BJDX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.8%
7d▼ 6.2%
14d▲ 12.7%
30d▲ 4.7%
ytd▼ 65.0%
1y▼ 84.4%
🏦Market Cap
$975,410
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
68
Fair

Trading Snapshot

Day Range
$0.94 – $0.96
52-Week Range
$0.80 – $16.68
Volume
$3.00B
Avg Volume
$3.84B
Shares Outstanding
1.0M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$116,120
Last Q Revenue
$30,739
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-49.44
Dividend Yield
—
Dilution (1yr)
+1021.0%

Why Investors Own BJDX

  • ✓High-growth profile — revenue up +45.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 55% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BJDX logo

BLUEJAY DIAGNOSTICS INC

BJDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$7M▼ −3.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▼ −23.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
449K▲ +1021.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$965K YoY
StockOtter · stockotter.space

About BLUEJAY DIAGNOSTICS INC

Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$1.18
▲ +24.9% Upside
High Target$1.37
Low Target$1.01
Based on 15 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

BLUEJAY DIAGNOSTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift BJDX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

BLUEJAY DIAGNOSTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.